Treatment of chronic hepatitis C in Asia: When East meets West
Ming‐Lung Yu(National Sun Yat-sen University), Wan‐Long Chuang(Kaohsiung Medical University)
Cited by 262
Related Papers
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
|Hepatology International|2020|295
Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|Liver International|2016|221
Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV
|Gastroenterology|2017|118
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus
|Metabolism|2024|111
2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations
|Journal of the Formosan Medical Association|2020|98